<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We observed the effects of a new thyrotropin-releasing hormone analogue, YM-14673 (N alpha-[[(S)-4-oxo-2-azetidinyl]<z:chebi fb="1" ids="23019">carbonyl</z:chebi>]-<z:chebi fb="0" ids="29979,32514">L-histidyl</z:chebi>-L-prolinamide dihydrate) on <z:hpo ids='HP_0000708'>behavioral changes</z:hpo> in 26 rats subjected to middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>The administration of 0.1 mg/kg i.p </plain></SENT>
<SENT sid="2" pm="."><plain>YM-14673 was started 1 week after occlusion and was repeated daily for 2 weeks </plain></SENT>
<SENT sid="3" pm="."><plain>YM-14673 significantly accelerated the recovery of neurologic deficits and ameliorated the disturbance of passive avoidance learning </plain></SENT>
<SENT sid="4" pm="."><plain>Thus, YM-14673 improved behavioral response in a model of <z:hpo ids='HP_0011010'>chronic</z:hpo> focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>The availability of a <z:hpo ids='HP_0011010'>chronic</z:hpo> middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> model for the evaluation of drugs is also discussed </plain></SENT>
</text></document>